{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:07:20Z","timestamp":1790381240685,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,22]]},"DOI":"10.7759\/cureus.14029","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T07:41:07Z","timestamp":1616398867000},"source":"Crossref","is-referenced-by-count":4,"title":["Vitiligo: The Association With Metabolic Syndrome and the Role of Simvastatin as an Immunomodulator"],"prefix":"10.7759","author":[{"given":"Deepak","family":"Verma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadija","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karez S","family":"Namiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amena","family":"Firoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Bouchama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maham","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Haris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2019.07.006","article-title":"Higher incidence of metabolic syndrome components in vitiligo patients: a prospective cross-sectional study","volume":"95","author":"Tanacan E","year":"2020","unstructured":"Tanacan E, Atakan N. Higher incidence of metabolic syndrome components in vitiligo patients: a prospective cross-sectional study. An Bras Dermatol. 2020, 95:165-72. 10.1016\/j.abd.2019.07.006","journal-title":"An Bras Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S257022","article-title":"Vitiligo and rise in blood pressure - a case-control study in a referral dermatology clinic in southern Iran","volume":"13","author":"Namazi MR","year":"2020","unstructured":"Namazi MR, Rouhani S, Moarref A, Kiani M, Tabei SS, Hadibarhaghtalab M. Vitiligo and rise in blood pressure - a case-control study in a referral dermatology clinic in southern Iran. Clin Cosmet Investig Dermatol. 2020, 13:425-30. 10.2147\/CCID.S257022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4274\/balkanmedj.2016.1005","article-title":"Increased risk of metabolic syndrome in patients with vitiligo","volume":"34","author":"Ata\u015f H","year":"2017","unstructured":"Ata\u015f H, G\u00f6n\u00fcl M. Increased risk of metabolic syndrome in patients with vitiligo. Balkan Med J. 2017, 34:219-25. 10.4274\/balkanmedj.2016.1005","journal-title":"Balkan Med J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdds.2017.06.001","article-title":"Association of vitiligo with anemia, vitamin B12 deficiency, diabetes mellitus, and thyroid dysfunction in Saudi Arab patients: a case control study","volume":"21","author":"Mubki T","year":"2017","unstructured":"Mubki T, Alissa A, Mulekar S, Albargawi S, Youssef M, AlJasser M. Association of vitiligo with anemia, vitamin B12 deficiency, diabetes mellitus, and thyroid dysfunction in Saudi Arab patients: a case control study. J Dermatol Dermatol Surg. 2017, 21:72-6. 10.1016\/j.jdds.2017.06.001","journal-title":"J Dermatol Dermatol Surg"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4103\/2229-5178.142493","article-title":"Increased prevalence of thyroid dysfunction and diabetes mellitus in Indian vitiligo patients: a case-control study","volume":"5","author":"Gopal KV","year":"2014","unstructured":"Gopal KV, Rao GR, Kumar YH. Increased prevalence of thyroid dysfunction and diabetes mellitus in Indian vitiligo patients: a case-control study. Indian Dermatol Online J. 2014, 5:456-60. 10.4103\/2229-5178.142493","journal-title":"Indian Dermatol Online J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.52.5.1210","article-title":"NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older","volume":"52","author":"Alexander CM","year":"2003","unstructured":"Alexander CM, Landsman PB, Teutsch SM, Haffner SM, Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003, 52:1210-4. 10.2337\/diabetes.52.5.1210","journal-title":"Diabetes"},{"key":"ref7","article-title":"Are patients with vitiligo more prone to myocardial infarction?: a case-control study","volume":"12","author":"Ahmed Abdel Rahman SH","year":"2019","unstructured":"Ahmed Abdel Rahman SH, Hussein MS, Mansour AI. Are patients with vitiligo more prone to myocardial infarction?: a case-control study. J Clin Aesthet Dermatol. 2019, 12:28-31.","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.01.020","article-title":"Simvastatin protects human melanocytes from H2O2-induced oxidative stress by activating Nrf2","volume":"137","author":"Chang Y","year":"2017","unstructured":"Chang Y, Li S, Guo W, et al.. Simvastatin protects human melanocytes from H2O2-induced oxidative stress by activating Nrf2. J Invest Dermatol. 2017, 137:1286-96. 10.1016\/j.jid.2017.01.020","journal-title":"J Invest Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.0906-6705.2004.00208.x","article-title":"Statins: novel additions to the dermatologic arsenal?","volume":"13","author":"Namazi MR","year":"2004","unstructured":"Namazi MR. Statins: novel additions to the dermatologic arsenal?. Exp Dermatol. 2004, 13:337-9. 10.1111\/j.0906-6705.2004.00208.x","journal-title":"Exp Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-018-3168-4","article-title":"The evaluation of vitiligous lesions repigmentation after the administration of atorvastatin calcium salt and simvastatin-acid sodium salt in patients with active vitiligo (EVRAAS), a pilot study: study protocol for a randomized controlled trial","volume":"20","author":"Niezgoda A","year":"2019","unstructured":"Niezgoda A, Winnicki A, Kosmalski T, Kowaliszyn B, Krysi\u0144ski J, Czajkowski R. The evaluation of vitiligous lesions repigmentation after the administration of atorvastatin calcium salt and simvastatin-acid sodium salt in patients with active vitiligo (EVRAAS), a pilot study: study protocol for a randomized controlled trial. Trials. 2019, 20:78. 10.1186\/s13063-018-3168-4","journal-title":"Trials"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher D","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009, 6:1000097. 10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12941","article-title":"Support for increased cardiovascular risk in non-segmental vitiligo among Egyptians: a hospital-based, case-control study [Online ahead of print]","author":"Azzazi Y","year":"2020","unstructured":"Azzazi Y, Mostafa WZ, Sayed KS, et al.. Support for increased cardiovascular risk in non-segmental vitiligo among Egyptians: a hospital-based, case-control study [Online ahead of print]. Pigment Cell Melanoma Res. 2020, 10.1111\/pcmr.12941","journal-title":"Pigment Cell Melanoma Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.14260\/jemds\/2019\/604","article-title":"Association of metabolic syndrome with vitiligo- a case control study","volume":"8","author":"Sinha PK","year":"2019","unstructured":"Sinha PK, Nigam P, Swain JP. Association of metabolic syndrome with vitiligo- a case control study. J Evolution Med Dent Sci. 2019, 8:2783-6. 10.14260\/jemds\/2019\/604","journal-title":"J Evolution Med Dent Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2004.01524.x","article-title":"Oxidant-antioxidant enzymes and lipid peroxidation in generalized vitiligo","volume":"29","author":"Koca R","year":"2004","unstructured":"Koca R, Armutcu F, Altinyazar HC, G\u00fcrel A. Oxidant-antioxidant enzymes and lipid peroxidation in generalized vitiligo. Clin Exp Dermatol. 2004, 29:406-9. 10.1111\/j.1365-2230.2004.01524.x","journal-title":"Clin Exp Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-009-0964-4","article-title":"Circulatory levels of antioxidants and lipid peroxidation in Indian patients with generalized and localized vitiligo","volume":"301","author":"Khan R","year":"2009","unstructured":"Khan R, Satyam A, Gupta S, Sharma VK, Sharma A. Circulatory levels of antioxidants and lipid peroxidation in Indian patients with generalized and localized vitiligo. Arch Dermatol Res. 2009, 301:731-7. 10.1007\/s00403-009-0964-4","journal-title":"Arch Dermatol Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2016.11.010","article-title":"Mitochondrial dysfunction and oxidative stress in metabolic disorders - a step towards mitochondria based therapeutic strategies","volume":"1863","author":"Bhatti JS","year":"2017","unstructured":"Bhatti JS, Bhatti GK, Reddy PH. Mitochondrial dysfunction and oxidative stress in metabolic disorders - a step towards mitochondria based therapeutic strategies. Biochim Biophys Acta Mol Basis Dis. 2017, 1863:1066-77. 10.1016\/j.bbadis.2016.11.010","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/10715762.2017.1402303","article-title":"Levels of oxidative damage and proinflammatory cytokines are enhanced in patients with active vitiligo","volume":"51","author":"Mitra S","year":"2017","unstructured":"Mitra S, De Sarkar S, Pradhan A, et al.. Levels of oxidative damage and proinflammatory cytokines are enhanced in patients with active vitiligo. Free Radic Res. 2017, 51:986-94. 10.1080\/10715762.2017.1402303","journal-title":"Free Radic Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1141","article-title":"Insulin resistance is increased in patients with vitiligo","volume":"91","author":"Karadag AS","year":"2011","unstructured":"Karadag AS, Tutal E, Ertugrul DT. Insulin resistance is increased in patients with vitiligo. Acta Derm Venereol. 2011, 91:541-4. 10.2340\/00015555-1141","journal-title":"Acta Derm Venereol"},{"key":"ref19","article-title":"Hepato-splenic and lipid profile abnormalities--do they exist in children affected with vitiligo?","volume":"22","author":"Pietrzak A","year":"2014","unstructured":"Pietrzak A, Bartosi\u0144ska J, Dybiec E, Chodorowska G, Krasowska D, Hercogova J, Lotti T. Hepato-splenic and lipid profile abnormalities--do they exist in children affected with vitiligo?. Acta Dermatovenerol Croat. 2014, 22:19-25.","journal-title":"Acta Dermatovenerol Croat"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0749.2000.130106.x","article-title":"Higher plasma catecholamine and metabolite levels in the early phase of nonsegmental vitiligo","volume":"13","author":"Cucchi ML","year":"2000","unstructured":"Cucchi ML, Frattini P, Santagostino G, Orecchia G. Higher plasma catecholamine and metabolite levels in the early phase of nonsegmental vitiligo. Pigment Cell Res. 2000, 13:28-32. 10.1034\/j.1600-0749.2000.130106.x","journal-title":"Pigment Cell Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1159\/000246877","article-title":"Normal-range plasma catecholamines in patients with generalized and acrofacial vitiligo: preliminary report","volume":"189","author":"Orecchia G","year":"1994","unstructured":"Orecchia G, Frattini P, Cucchi ML, Santagostino G. Normal-range plasma catecholamines in patients with generalized and acrofacial vitiligo: preliminary report. Dermatology. 1994, 189:350-3. 10.1159\/000246877","journal-title":"Dermatology"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.7754\/Clin.Lab.2020.200120","article-title":"Lipid risk factors in vitiligo: homocysteine the connecting link?","volume":"66","author":"Taneja K","year":"2020","unstructured":"Taneja K, Taneja J, Kaur C, Patel S, Haldar D. Lipid risk factors in vitiligo: homocysteine the connecting link?. Clin Lab. 2020, 66:10. 10.7754\/Clin.Lab.2020.200120","journal-title":"Clin Lab"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.08.029","article-title":"Serum homocysteine, folate, and vitamin B12\u00a0levels in patients with vitiligo and their potential roles as disease activity biomarkers: a systematic review and meta-analysis","volume":"80","author":"Tsai TY","year":"2019","unstructured":"Tsai TY, Kuo CY, Huang YC. Serum homocysteine, folate, and vitamin B12\u00a0levels in patients with vitiligo and their potential roles as disease activity biomarkers: a systematic review and meta-analysis. J Am Acad Dermatol. 2019, 80:646-54. 10.1016\/j.jaad.2018.08.029","journal-title":"J Am Acad Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.20442","article-title":"Increased level of serum homocysteine in vitiligo","volume":"25","author":"Singh S","year":"2011","unstructured":"Singh S, Singh U, Pandey SS. Increased level of serum homocysteine in vitiligo. J Clin Lab Anal. 2011, 25:110-2. 10.1002\/jcla.20442","journal-title":"J Clin Lab Anal"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00803","article-title":"The prevalence of thyroid disorders in patients with vitiligo: a systematic review and meta-analysis","volume":"9","author":"Yuan J","year":"2019","unstructured":"Yuan J, Sun C, Jiang S, et al.. The prevalence of thyroid disorders in patients with vitiligo: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2019, 9:803. 10.3389\/fendo.2018.00803","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00163","article-title":"Thyroid dysfunction and diabetes mellitus: two closely associated disorders","volume":"40","author":"Biondi B","year":"2019","unstructured":"Biondi B, Kahaly GJ, Robertson RP. Thyroid dysfunction and diabetes mellitus: two closely associated disorders. Endocr Rev. 2019, 40:789-824. 10.1210\/er.2018-00163","journal-title":"Endocr Rev"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.022","article-title":"The association between vitiligo and diabetes mellitus: a systematic review and meta-analysis","volume":"81","author":"Chang HC","year":"2019","unstructured":"Chang HC, Lin MH, Huang YC, Hou TY. The association between vitiligo and diabetes mellitus: a systematic review and meta-analysis. J Am Acad Dermatol. 2019, 81:1442-5. 10.1016\/j.jaad.2019.06.022","journal-title":"J Am Acad Dermatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.15537\/smj.2017.4.17551","article-title":"Chronic diseases among vitiligo patients. A case control study","volume":"38","author":"Al Houssien AO","year":"2017","unstructured":"Al Houssien AO, Al Houssien RO, Al Ajroush W, Al Kahtani HS. Chronic diseases among vitiligo patients. A case control study. Saudi Med J. 2017, 38:400-4. 10.15537\/smj.2017.4.17551","journal-title":"Saudi Med J"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2016.12.009","article-title":"Metabolic syndrome in vitiligo patients among a semi-urban Maharashtrian population: a case control study","volume":"11","author":"Sharma YK","year":"2017","unstructured":"Sharma YK, Bansal P, Menon S, Prakash N. Metabolic syndrome in vitiligo patients among a semi-urban Maharashtrian population: a case control study. Diabetes Metab Syndr. 2017, 11:77-80. 10.1016\/j.dsx.2016.12.009","journal-title":"Diabetes Metab Syndr"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.5336\/medsci.2018-60404","article-title":"The relationship of vitiligo with insulin resistance and metabolic syndrome [Article in Turkish]","volume":"38","author":"Onan DT","year":"2018","unstructured":"Onan DT, Tantoglu BH, Artuz F, et al.. The relationship of vitiligo with insulin resistance and metabolic syndrome [Article in Turkish]. Turkiye Klinikleri J Med Sci. 2018, 38:241-7. 10.5336\/medsci.2018-60404","journal-title":"Turkiye Klinikleri J Med Sci"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12148","article-title":"Prevalence of vitiligo among type 2 diabetic patients in an Iranian population","volume":"53","author":"Afkhami-Ardekani M","year":"2014","unstructured":"Afkhami-Ardekani M, Ghadiri-Anari A, Ebrahimzadeh-Ardakani M, Zaji N. Prevalence of vitiligo among type 2 diabetic patients in an Iranian population. Int J Dermatol. 2014, 53:956-8. 10.1111\/ijd.12148","journal-title":"Int J Dermatol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.IJD_360_16","article-title":"A study of vitiligo in type 2 diabetic patients","volume":"62","author":"Raveendra L","year":"2017","unstructured":"Raveendra L, Hemavathi RN, Rajgopal S. A study of vitiligo in type 2 diabetic patients. Indian J Dermatol. 2017, 62:168-70. 10.4103\/ijd.IJD_360_16","journal-title":"Indian J Dermatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.06.015","article-title":"A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo","volume":"76","author":"Vanderweil SG","year":"2017","unstructured":"Vanderweil SG, Amano S, Ko WC, et al.. A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo. J Am Acad Dermatol. 2017, 76:150-1. 10.1016\/j.jaad.2016.06.015","journal-title":"J Am Acad Dermatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2020-001390","article-title":"Efficacy and safety of oral simvastatin in the treatment of patients with vitiligo","volume":"69","author":"Zhang S","year":"2021","unstructured":"Zhang S, Zdravkovi\u0107 TP, Wang T, Liu Y, Jin H. Efficacy and safety of oral simvastatin in the treatment of patients with vitiligo. J Investig Med. 2021, 69:393-6. 10.1136\/jim-2020-001390","journal-title":"J Investig Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1186\/1476-511X-3-7","article-title":"Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo","volume":"3","author":"No\u00ebl M","year":"2004","unstructured":"No\u00ebl M, Gagn\u00e9 C, Bergeron J, Jobin J, Poirier P. Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo. Lipids Health Dis. 2004, 3:7. 10.1186\/1476-511X-3-7","journal-title":"Lipids Health Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/53553-vitiligo-the-association-with-metabolic-syndrome-and-the-role-of-simvastatin-as-an-immunomodulator","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:31:04Z","timestamp":1707507064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/53553-vitiligo-the-association-with-metabolic-syndrome-and-the-role-of-simvastatin-as-an-immunomodulator"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,22]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.14029","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,22]]}}}